Cancer Immunology, Immunotherapy

, Volume 52, Issue 12, pp 739–750

Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model

  • Maryam Parviz
  • Cynthia S. Chin
  • Laura J. Graham
  • Catriona Miller
  • Catherine Lee
  • Kimberly George
  • Harry D. Bear
Original Article


Tumor cell vaccines have been successful at inducing immunity in naïve mice, but only in a few reports has vaccination alone induced regression of established tumors and, generally, only when they are very small. Clinically, vaccinations alone may not be able to cause regression of established human cancers, which tend to be weakly immunogenic. We hypothesized that pharmacologic ex vivo amplification of a vaccination-induced immune response with subsequent adoptive immunotherapy (AIT) to tumor-bearing animals would be more effective in treatment of these animals than vaccination alone. The 4T1 and 4T07 mammary carcinomas are derived from the same parental cell line, but 4T1 is much less immunogenic and more aggressive than 4T07. Vaccination with either 4T1, 4T1-IL-2, or 4T07-IL-2 was not effective as treatment for established 4T1 tumors. However, 4T1 or 4T07-IL-2-vaccine-sensitized draining lymph node (DLN) cells, activated ex vivo with bryostatin 1 and ionomycin and expanded in culture, induced complete tumor regressions when adoptively transferred to 4T1 tumor-bearing animals. This was effective against small tumors as well as more advanced tumors, 10 days after tumor cell inoculation. Furthermore, as would be required for this approach to be used clinically, vaccine-DLN cells obtained from mice with established progressive 4T1 tumors (inoculated 10 days before vaccination) also induced regression of 4T1 tumors in an adoptive host. In none of these experiments was exogenous IL-2 required to induce tumor regression. The response to tumor cell vaccine can be amplified by ex vivo pharmacologic activation of sensitized T cells, which can then cure an established, weakly immunogenic and highly aggressive tumor that was resistant to vaccination alone.


Bryostatin 1 Ionomycin Adoptive immunotherapy Cyclophosphamide 4T1 


  1. 1.
    Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399PubMedGoogle Scholar
  2. 2.
    Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunol 65:87Google Scholar
  3. 3.
    Barth RJ Jr., Mulé JJ, Spiess PJ, Rosenberg SA (1991) Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by CD8+ tumor-infiltrating lymphocytes. J Exp Med 173:647PubMedGoogle Scholar
  4. 4.
    Bass KK, Mastrangelo MJ (1998) Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47:1PubMedGoogle Scholar
  5. 5.
    Becker C, Pohla H, Frankenberger B, Schendel DJ, Assenmacher M, Schendel, Blankenstein T (2001) Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nature Med 7:1159CrossRefPubMedGoogle Scholar
  6. 6.
    Berd D, Mastrangelo MJ, Engstrom PF, Paul A, Maguire H (1982) Augmentation of the human immune response by cyclophosphamide. Cancer Res 42(11):4862PubMedGoogle Scholar
  7. 7.
    Cantrell D (1996) T cell antigen receptor signal transduction pathways. Annu Rev Immunol 14:259PubMedGoogle Scholar
  8. 8.
    Chamberlain RS, Carroll MW, Bronte V, Hwu P, Warren S, Yang JC, Nishimura M, Moss B, Rosenberg SA, Restifo NP (1996) Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 56:2832PubMedGoogle Scholar
  9. 9.
    Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM, Wu T (2000) Antigen-specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer 86:725CrossRefPubMedGoogle Scholar
  10. 10.
    Chin CS, Bear HD (2002) Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunologic activity. Ann Surg Oncol 9:94CrossRefPubMedGoogle Scholar
  11. 11.
    Chin CS, Graham LJ, Hamad GG, George KR, Bear HD (2001) Bryostatin/ionomycin-activated T cells mediate regression of established tumors. J Surg Res 98:108CrossRefPubMedGoogle Scholar
  12. 12.
    Chin CS, Nguyen H, Bear HD (2001) Bryostatin 1/Ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Surg Forum 52:262Google Scholar
  13. 13.
    Chou T, Chang AE, Shu SY (1988) Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity. J Immunol 140(7):2453PubMedGoogle Scholar
  14. 14.
    Dranoff, G. (1998) Cancer gene therapy: connecting basic research with clinical inquiry. J Clin Oncol 16:2548–2556Google Scholar
  15. 15.
    Egilmez NK, Jong YS, Sabel MS, Jacob JS, Mathiowitz E, Bankert RB (2000) In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res 60:3832PubMedGoogle Scholar
  16. 16.
    Jaffee EM (1999) Immunotherapy of cancer. Ann N Y Acad Sci 886:67PubMedGoogle Scholar
  17. 17.
    Jensen SM, Hu H-M, Fox BA (2001) Increased IFN-γ secretion by adoptively transferred T cells does not correlate with enhanced anti-tumor therapy. Proceedings of the AACR, 42:502Google Scholar
  18. 18.
    Jiang XP, Yang DC, Elliott RL, Head JF (2000) Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15–3, CEA and CA125—results in immune and clinical responses in breast cancer patients. Cancer Biother Radiopharm 15:495PubMedGoogle Scholar
  19. 19.
    Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang R-F, Restifo NP, Hwu P (2001) Immunization against endogenous retroviral tumor-associated antigens. Cancer Res 61:7920PubMedGoogle Scholar
  20. 20.
    Kessels HWHG, Wolkers MC, van der Boom MD, Van der Valk MA, Schumacher TNM (2001) Immunotherapy through TCR gene transfer. Nature Immunol 2:957CrossRefGoogle Scholar
  21. 21.
    Li Y, Hellström KE, Newby SA, Chen LP (1996) Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J Exp Med 183:639PubMedGoogle Scholar
  22. 22.
    Lohr F, Hu K, Haroon Z, Samulski TV, Huang Q, Beaty J, Dewhirst MW, Li CY (2000) Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. Mol Ther 2:195CrossRefPubMedGoogle Scholar
  23. 23.
    Luznik L, Slansky JE, Jalla S, Borrello I, Levitsky HI, Pardoll DM, Fuchs EJ (2003) Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood 101:1645Google Scholar
  24. 24.
    Maguire HC Jr, Ettore VL (1967) Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J Invest Dermatol 48(1):39PubMedGoogle Scholar
  25. 25.
    Morecki S, Yacovlev E, Diab A, Slavin S (1998) Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res 58:3891PubMedGoogle Scholar
  26. 26.
    Morecki S, Yacovlev E, Gelfand Y, Uzi H, Slavin S (2001) Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother Emphasis Tumor Immunol 24:114CrossRefGoogle Scholar
  27. 27.
    Peng L, Krauss JC, Plautz GE, Mukai S, Shu S, Cohen PA (2000) T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ mechanisms that cannot be predicted from in vitro T cell characteristics. J Immunol 165:7116PubMedGoogle Scholar
  28. 28.
    Proietti E, Greco G, Garrone B, Baccarini S, Mauri C, Venditti M, Carlei D, Belardelli F (1998) Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest 101:429PubMedGoogle Scholar
  29. 29.
    Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58:1486PubMedGoogle Scholar
  30. 30.
    Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S (2000) Cooperativity of Staphylococcal aureus entertoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 60:2710PubMedGoogle Scholar
  31. 31.
    Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arioli I, Parmiani G, Colombo MP (1996) Immunotherapy of experimental metastases by vaccination with interleukin gene-transduced adenocarcinoma cells sharing tumor-associated antigens—comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines. J Immunol 157:5536PubMedGoogle Scholar
  32. 32.
    Shu S, Krinock RA, Matsumura T, Sussman JJ, Fox BA, Chang AE, Terman DS (1994) Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J Immunol 152:1277PubMedGoogle Scholar
  33. 33.
    Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, Margulies DH, Pardoll DM (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TcR complex. Immunity 13:529PubMedGoogle Scholar
  34. 34.
    Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hodi FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KK, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S (1998) Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA 95:13141PubMedGoogle Scholar
  35. 35.
    Stanislawski T, Voss R-H, Lotz C, Sadovnikova E, Willemsen RA, Kuball J, Ruppert T, Bolhuis RLH, Melief CJ, Huber C, Stauss HJ, Theobald M (2001) Circumventing tolerance to a human MDM 2-derived tumor antigen by TCR gene transfer. Nature Immunology 2:962CrossRefPubMedGoogle Scholar
  36. 36.
    Tsung K, Meko JB, Peplinski GR, Tsung TL, Norton JA (1997) IL-12 induces T helper-1 directed antitumor responses. J Immunol 158:3359PubMedGoogle Scholar
  37. 37.
    Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA (1998) Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J Immunol 160:1369PubMedGoogle Scholar
  38. 38.
    Tuting T, Storkus WJ, Lotze MT (1997) Gene-based strategies for the immunotherapy of cancer. J Mol Med 75:478CrossRefPubMedGoogle Scholar
  39. 39.
    Tuttle TM, Bethke KP, Inge TH, McCrady CW, Pettit GR, Bear HD (1992) Bryostatin 1-activated T cells can traffic and mediate tumor regression. J Surg Res 52:543PubMedGoogle Scholar
  40. 40.
    Tuttle TM, Inge TH, Bethke KP, McCrady CW, Pettit GR, Bear HD (1992) Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res 52:548PubMedGoogle Scholar
  41. 41.
    Tuttle TM, Fleming MF, Hogg PS, Inge TH, Bear HD (1994) Low-dose cyclophosphamide overcomes metastasis-induced immunosuppression. Ann Surg Oncol 1:53PubMedGoogle Scholar
  42. 42.
    Tuttle TM, Inge TH, Wirt CP, Frank JL, McCrady CM, Bear HD (1992) Bryostatin 1 activates T cells that have antitumor activity. J Immunother Emphasis Tumor Immunol 12:75Google Scholar
  43. 43.
    Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD (1993) γ-Interferon plays a key role in T-cell-induced tumor regression. Cancer Res 53:833PubMedGoogle Scholar
  44. 44.
    Winter H, Hu H-M, McClain K, Urba WJ, Fox BA (2001) Immunotherapy of melanoma: A dichotomy in the requirement for IFN-γ in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol 166:7370PubMedGoogle Scholar
  45. 45.
    Wise JA, Mokyr MB, Dray S (1988) Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas. Cancer Immunol Immunother 27:191PubMedGoogle Scholar
  46. 46.
    Wittig B, Marten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Loffel J, Neubauer A, Albers P, Muller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG (2001) Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 12:267PubMedGoogle Scholar
  47. 47.
    Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT (1995) Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 155:1393PubMedGoogle Scholar
  48. 48.
    Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T (1995) Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol 7:1135PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Maryam Parviz
    • 1
  • Cynthia S. Chin
    • 1
    • 3
  • Laura J. Graham
    • 1
  • Catriona Miller
    • 2
  • Catherine Lee
    • 1
  • Kimberly George
    • 1
    • 2
  • Harry D. Bear
    • 1
    • 2
    • 4
  1. 1.Department of Surgery and the Massey Cancer CenterVirginia Commonwealth University's Medical College of VirginiaRichmondUSA
  2. 2.Department of Microbiology and ImmunologyVirginia Commonwealth University's Medical College of VirginiaRichmondUSA
  3. 3.St Vincent's Medical CenterNew YorkUSA
  4. 4.Division of Surgical OncologyVirginia Commonwealth University's Medical College of VirginiaRichmondUSA

Personalised recommendations